Literature DB >> 31775037

Differential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis.

SungHee Park1, Mattia Brugiolo1, Martin Akerman2, Shipra Das3, Laura Urbanski4, Adam Geier5, Anil K Kesarwani1, Martin Fan3, Nathan Leclair4, Kuan-Ting Lin3, Leo Hu3, Ian Hua3, Joshy George6, Senthil K Muthuswamy7, Adrian R Krainer8, Olga Anczuków9.   

Abstract

Misregulation of alternative splicing is a hallmark of human tumors, yet to what extent and how it contributes to malignancy are only beginning to be unraveled. Here, we define which members of the splicing factor SR and SR-like families contribute to breast cancer and uncover differences and redundancies in their targets and biological functions. We identify splicing factors frequently altered in human breast tumors and assay their oncogenic functions using breast organoid models. We demonstrate that not all splicing factors affect mammary tumorigenesis in MCF-10A cells. Specifically, the upregulation of SRSF4, SRSF6, or TRA2β disrupts acinar morphogenesis and promotes cell proliferation and invasion in MCF-10A cells. By characterizing the targets of these oncogenic splicing factors, we identify shared spliced isoforms associated with well-established cancer hallmarks. Finally, we demonstrate that TRA2β is regulated by the MYC oncogene, plays a role in metastasis maintenance in vivo, and its levels correlate with breast cancer patient survival.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MYC; SR protein; TRA2-beta; alternative RNA splicing; breast cancer; metastasis; splicing factor; triple negative breast cancer

Mesh:

Substances:

Year:  2019        PMID: 31775037      PMCID: PMC6936330          DOI: 10.1016/j.celrep.2019.10.110

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.995


  110 in total

1.  Involvement of SR proteins in mRNA surveillance.

Authors:  Zuo Zhang; Adrian R Krainer
Journal:  Mol Cell       Date:  2004-11-19       Impact factor: 17.970

2.  Distinct functions of SR proteins in alternative pre-mRNA splicing.

Authors:  A M Zahler; K M Neugebauer; W S Lane; M B Roth
Journal:  Science       Date:  1993-04-09       Impact factor: 47.728

3.  The lipid kinase PI4KIIIβ and the eEF1A2 oncogene co-operate to disrupt three-dimensional in vitro acinar morphogenesis.

Authors:  Dixie E Pinke; Jonathan M Lee
Journal:  Exp Cell Res       Date:  2011-08-07       Impact factor: 3.905

4.  Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC.

Authors:  Shipra Das; Olga Anczuków; Martin Akerman; Adrian R Krainer
Journal:  Cell Rep       Date:  2012-02-23       Impact factor: 9.423

5.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene.

Authors:  Rotem Karni; Elisa de Stanchina; Scott W Lowe; Rahul Sinha; David Mu; Adrian R Krainer
Journal:  Nat Struct Mol Biol       Date:  2007-02-18       Impact factor: 15.369

6.  Differential analysis of gene regulation at transcript resolution with RNA-seq.

Authors:  Cole Trapnell; David G Hendrickson; Martin Sauvageau; Loyal Goff; John L Rinn; Lior Pachter
Journal:  Nat Biotechnol       Date:  2012-12-09       Impact factor: 54.908

7.  Identification of alternative splicing markers for breast cancer.

Authors:  Julian P Venables; Roscoe Klinck; Anne Bramard; Lyna Inkel; Geneviève Dufresne-Martin; ChuShin Koh; Julien Gervais-Bird; Elvy Lapointe; Ulrike Froehlich; Mathieu Durand; Daniel Gendron; Jean-Philippe Brosseau; Philippe Thibault; Jean-Francois Lucier; Karine Tremblay; Panagiotis Prinos; Raymund J Wellinger; Benoit Chabot; Claudine Rancourt; Sherif Abou Elela
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

8.  Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins.

Authors:  Stephanie C Huelga; Anthony Q Vu; Justin D Arnold; Tiffany Y Liang; Patrick P Liu; Bernice Y Yan; John Paul Donohue; Lily Shiue; Shawn Hoon; Sydney Brenner; Manuel Ares; Gene W Yeo
Journal:  Cell Rep       Date:  2012-02-23       Impact factor: 9.423

9.  SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.

Authors:  Eunhee Kim; Janine O Ilagan; Yang Liang; Gerrit M Daubner; Stanley C-W Lee; Aravind Ramakrishnan; Yue Li; Young Rock Chung; Jean-Baptiste Micol; Michele E Murphy; Hana Cho; Min-Kyung Kim; Ahmad S Zebari; Shlomzion Aumann; Christopher Y Park; Silvia Buonamici; Peter G Smith; H Joachim Deeg; Camille Lobry; Iannis Aifantis; Yorgo Modis; Frederic H-T Allain; Stephanie Halene; Robert K Bradley; Omar Abdel-Wahab
Journal:  Cancer Cell       Date:  2015-05-11       Impact factor: 31.743

10.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.

Authors:  Edward Y Chen; Christopher M Tan; Yan Kou; Qiaonan Duan; Zichen Wang; Gabriela Vaz Meirelles; Neil R Clark; Avi Ma'ayan
Journal:  BMC Bioinformatics       Date:  2013-04-15       Impact factor: 3.169

View more
  26 in total

Review 1.  Canonical Wnt: a safeguard and threat for erythropoiesis.

Authors:  Rosa A Krimpenfort; Micha Nethe
Journal:  Blood Adv       Date:  2021-09-28

2.  SFPQ promotes RAS-mutant cancer cell growth by modulating 5'-UTR mediated translational control of CK1α.

Authors:  Venetia Jing Tong Kok; Jia Ying Tang; Gracie Wee Ling Eng; Shin Yi Tan; Joseph Tin Foong Chin; Chun Hian Quek; Wei Xuan Lai; Teck Kwang Lim; Qingsong Lin; John Jia En Chua; Jit Kong Cheong
Journal:  NAR Cancer       Date:  2022-09-27

3.  Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas.

Authors:  Muthana Al Abo; Terry Hyslop; Xiaodi Qin; Kouros Owzar; Daniel J George; Steven R Patierno; Jennifer A Freedman
Journal:  Genomics       Date:  2021-03-08       Impact factor: 5.736

4.  KSR1- and ERK-dependent translational regulation of the epithelial-to-mesenchymal transition.

Authors:  Chaitra Rao; Danielle E Frodyma; Siddesh Southekal; Robert A Svoboda; Adrian R Black; Chittibabu Guda; Tomohiro Mizutani; Hans Clevers; Keith R Johnson; Kurt W Fisher; Robert E Lewis
Journal:  Elife       Date:  2021-05-10       Impact factor: 8.140

5.  SRSF6 Regulates the Alternative Splicing of the Apoptotic Fas Gene by Targeting a Novel RNA Sequence.

Authors:  Namjeong Choi; Ha Na Jang; Jagyeong Oh; Jiyeon Ha; Hyungbin Park; Xuexiu Zheng; Sunjae Lee; Haihong Shen
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

6.  Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes.

Authors:  Deeksha Malhan; Alireza Basti; Angela Relógio
Journal:  NPJ Syst Biol Appl       Date:  2022-05-12

Review 7.  Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.

Authors:  Flavia Zita Francies; Rodney Hull; Richard Khanyile; Zodwa Dlamini
Journal:  Am J Cancer Res       Date:  2020-05-01       Impact factor: 5.942

Review 8.  Splicing alterations in healthy aging and disease.

Authors:  Brittany Lynn Angarola; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-02-09       Impact factor: 9.957

9.  The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.

Authors:  Michalina Janiszewska; Shayna Stein; Otto Metzger Filho; Jennifer Eng; Natalie L Kingston; Nicholas W Harper; Inga H Rye; Maša Alečković; Anne Trinh; Katherine C Murphy; Elisabetta Marangoni; Simona Cristea; Benjamin Oakes; Eric P Winer; Ian E Krop; Hege G Russnes; Paul T Spellman; Elmar Bucher; Zhi Hu; Koei Chin; Joe W Gray; Franziska Michor; Kornelia Polyak
Journal:  JCI Insight       Date:  2021-06-08

10.  Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.

Authors:  Jaclyn M Einstein; Mark Perelis; Isaac A Chaim; Jitendra K Meena; Julia K Nussbacher; Alexandra T Tankka; Brian A Yee; Heyuan Li; Assael A Madrigal; Nicholas J Neill; Archana Shankar; Siddhartha Tyagi; Thomas F Westbrook; Gene W Yeo
Journal:  Mol Cell       Date:  2021-07-02       Impact factor: 19.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.